Lipocine Withdraws Preliminary Injunction Threat Against Marketing of Clarus Therapeutics' JATENZO® Product: Trial Date Set for August 2020 - GlobeNewswire

Lipocine Withdraws Preliminary Injunction Threat Against Marketing of Clarus Therapeutics' JATENZO® Product: Trial Date Set for August 2020  GlobeNewswire

NORTHBROOK, Ill., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Clarus today announced that Lipocine, Inc. has confirmed that it will not seek preliminary injunctive ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more